Detalhe da pesquisa
1.
Cancers of Unknown Primary Origin: Real-World Clinical Outcomes and Genomic Analysis at the European Institute of Oncology.
Oncologist
; 29(6): 504-510, 2024 Jun 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38520742
2.
Biomarkers for Antibody-Drug Conjugates in Solid Tumors.
Mol Cancer Ther
; 23(4): 436-446, 2024 Apr 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38363729
3.
Primary malignant phyllodes tumors of the breast: A retrospective analysis from a referral center.
Eur J Cancer
; 196: 113423, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37977104
4.
Tumor Infiltrating Lymphocytes across Breast Cancer Subtypes: Current Issues for Biomarker Assessment.
Cancers (Basel)
; 15(3)2023 Jan 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-36765724
5.
Treatment optimization in early triple negative breast cancer.
Expert Rev Anticancer Ther
; 23(10): 1107-1116, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37873652
6.
Comparison of real-world data (RWD) analysis on efficacy and post-progression outcomes with pembrolizumab plus chemo vs chemo alone in metastatic non-squamous non-small cell lung cancer with PD-L1 < 50.
Front Oncol
; 12: 980765, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36033444